SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 29, Issue 7, 2011, Pages 783-786

Genetic predisposition for chemotherapy-induced neuropathy in multiple myeloma

(1) Becker, Pamela S a

a UNIVERSITY OF WASHINGTON (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DEXAMETHASONE; DOXORUBICIN; GABAPENTIN; GLUTAMINE; LENALIDOMIDE; LEVACECARNINE; MELPHALAN; PREDNISONE; PREGABALIN; PYRIDOXINE; THALIDOMIDE; THIOCTIC ACID; VINCRISTINE;

CAMKK1 GENE; CANCER COMBINATION CHEMOTHERAPY; DIABETIC NEUROPATHY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; GENE; GENETIC PREDISPOSITION; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; NEUROPATHIC PAIN; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SERPINB2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SLC12A6 GENE; SPRR1A GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DOXORUBICIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VINCRISTINE;

EID: 79952354221 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2010.33.4771 Document Type: Editorial

Times cited : (6)

References (8)

1
- 79952322815
- Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma
- Johnson DC, Corthals SL, Walker BA, et al: Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 29:797-804, 2011
- (2011) J Clin Oncol , vol.29 , pp. 797-804
- Johnson, D.C.¹ Corthals, S.L.² Walker, B.A.³

2
- 33644898842
- A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
- DOI 10.1111/j.1365-2141.2005.05914.x
- Glasmacher A, Hahn C, Hoffmann F, et al: A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132:584-593, 2006 (Pubitemid 43381591)
- (2006) British Journal of Haematology , vol.132 , Issue.5 , pp. 584-593
- Glasmacher, A.¹ Hahn, C.² Hoffmann, F.³ Naumann, R.⁴ Goldschmidt, H.⁵ Von Lilienfeld-Toal, M.⁶ Orlopp, K.⁷ Schmidt-Wolf, I.⁸ Gorschluter, M.⁹

3
- 51649117633
- A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
- von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al: A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 81:247-252, 2008
- (2008) Eur J Haematol , vol.81 , pp. 247-252
- Von Lilienfeld-Toal, M.¹ Hahn-Ast, C.² Furkert, K.³

4
- 70249146895
- Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy
- Richardson PG, Xie W, Mitsiades C, et al: Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518-3525, 2009
- (2009) J Clin Oncol , vol.27 , pp. 3518-3525
- Richardson, P.G.¹ Xie, W.² Mitsiades, C.³

5
- 79952331940
- Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalanprednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study
- Epub ahead of print on September 28
- Dimopoulos MA, Mateos MV, Richardson PG, et al: Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib- melphalanprednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study. Eur J Haematol [Epub ahead of print on September 28, 2010]
- (2010) Eur J Haematol
- Dimopoulos, M.A.¹ Mateos, M.V.² Richardson, P.G.³

6
- 78049528598
- Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65/GMMGHD4 trial
- Broyl A, Corthals SL, Jongen JL, et al: Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65/GMMGHD4 trial. Lancet Oncol 11:1057-1065, 2010
- (2010) Lancet Oncol , vol.11 , pp. 1057-1065
- Broyl, A.¹ Corthals, S.L.² Jongen, J.L.³

7
- 78049435885
- Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity
- van Kuilenburg AB, Meijer J, Mul AN, et al: Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 128:529-538, 2010
- (2010) Hum Genet , vol.128 , pp. 529-538
- Van Kuilenburg, A.B.¹ Meijer, J.² Mul, A.N.³

8
- 58149390981
- Single nucleotide polymorphism analysis in the GSTP1 and ABCC2 genes about neuropathy by the Oxaliplatin
- Mori Y, Katsumata K, Tsuchida A, et al: Single nucleotide polymorphism analysis in the GSTP1 and ABCC2 genes about neuropathy by the Oxaliplatin. Gan To Kagaku Ryoho35:2377-2381, 2008
- (2008) Gan to Kagaku Ryoho , vol.35 , pp. 2377-2381
- Mori, Y.¹ Katsumata, K.² Tsuchida, A.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.